The first patient has been dosed in a small clinical trial in Australia that’s testing CTx1000, Celosia Therapeutics’ experimental gene therapy, in people with amyotrophic lateral sclerosis (ALS). The one-time treatment is designed to reduce toxic buildups of the TDP-43 protein, which are believed to contribute to nerve cell…